Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
History of hypersensitivity to Chinese hamster ovary (CHO) cells or other human or humanized recombinant antibodies.
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies.
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to any of the components of cergutuzumab amunaleukin and atezolizumab; hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
GENERAL: Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Documented allergy or hypersensitivity to monoclonal antibodies (bevacizumab), to Chinese hamster ovarian cells of the or to any other humanized or recombinant antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or any of the study drugs
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
Patients must not have known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity of Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biologic composition to bevacizumab
Known hypersensitivity to Chinese hamster ovary cell products or to recombinant human or murine antibodies, or any of the treatments in this protocol
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
Known hypersensitivity to bevacizumab, Chinese hamster ovary cell products, or other recombinant human or humanized antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to any component of recombinant protein production by Chinese Hamster Ovary (CHO) cells
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Known hypersensitivity to any component of recombinant protein production by Chinese Hamster Ovary (CHO) cells
Prior hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies (Phase I and II)
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, and patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in the study
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies including hypersensitivity to any component of bevacizumab
Patient must not have a known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
Have a known hypersensitivity or allergy to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab and/or bevacizumab formulations
No known hypersensitivity to Chinese hamster ovary (CHO) cell products or any component of the atezolizumab formulation
The patient must NOT have a known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells.
Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab formulation, or any component of the cobimetinib formulation
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells
Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab, cobimetinib, or vemurafenib formulations
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any components of cobimetinib, atezolizumab, or bevacizumab formulations
Known hypersensitivity to Chinese hamster ovary (CHO) cell products or any component of the MPDL3280A formulation
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
Known hypersensitivity allergy or contraindication to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the PD-1/PD-L1 inhibitor formulation;
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or to any component of the atezolizumab formulation
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab or bevacizumab formulation
Known hypersensitivity or allergy to Chinese hamster ovary cell products or any component of the MDPL3280A formulation
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or to any component of the atezolizumab formulation
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or other recombinant antibodies
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab or guadecitabine formulations
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation.
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation or known hypersensitivity to any component of cobimetinib or vemurafenib
Known hypersensitivity to pharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab, obinutuzumab, rituximab, or bendamustine formulation, including mannitol
Known hypersensitivity to Chinese hamster ovary cell products or any component of the atezolizumab formulation
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cell or any component of the atezolizumab formulation
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation, emactuzumab formulation, or obinutuzumab formulation
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or other recombinant human antibodies
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
